Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.
about
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinaseKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaCharacterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathwayModeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug designMapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides.Peptide aptamers: recent developments for cancer therapy.A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in miceInhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cellsHigh affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.Bone marrow transplant in Ph+ ALL patients.The critical role of agrin in the hematopoietic stem cell niche.Targeted therapies in oncology: in the crosshairs or at the crossroads?Agrin is required for survival and function of monocytic cellsDevelopment of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.Cell penetrating peptides to dissect host-pathogen protein-protein interactions in Theileria-transformed leukocytes.BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.Grb2 signaling in cell motility and cancer
P2860
Q24563301-B0F69E65-0EE0-45D2-A732-D5B69553D02CQ26849792-1E983189-139D-470F-A6A9-01A6B3003C3BQ27025242-A33F074A-E7E7-43B1-84D0-6F39806207AEQ28206167-A41401EA-E34E-406F-A969-7B9FF0FD3E12Q28478748-933C0FDC-AA42-48E3-8B18-D4CB3F85050EQ30009317-6D40C162-BEB5-4468-A50C-66C7CEA20D2CQ30010259-97D8F02B-E2FF-45E4-A2AF-2DCBBF54E52DQ33216999-D612DE36-1E44-4789-A398-9FFEF31F6968Q33510153-9FAF531F-2AEE-4391-894F-A85E857959EEQ34565011-42419603-7C75-4310-9040-A1B199F30E48Q35104353-15E13AE7-72DE-42F5-89FF-145665181049Q35106125-C9DFB264-8EE2-40B8-A2D5-D5D21E9FC567Q35212352-3CECEC93-D7F8-419E-8BFA-27A6768768FEQ35641209-7859AE24-EDB6-4E16-A146-50A03469444AQ36015218-9DE4BB5F-C262-4171-9EB6-98EFB08550D3Q36429603-FE22637B-DDF4-4233-BB21-44E1E5416332Q40709933-77CCAA87-3D59-42E2-BCCA-8854BBFC7FA8Q41997461-198C18C4-3070-4E1C-9C40-82BE5835B417Q44040285-F2CF4E40-29E1-4927-A3CB-070F3B0FBA4DQ58199697-300436DB-C645-4FFA-9DE1-78ED3112AC71
P2860
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@ast
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@en
type
label
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@ast
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@en
prefLabel
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@ast
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@en
P2093
P356
P1433
P1476
Chronic myelogenous leukemia b ...... at disrupt Grb2-SoS complexes.
@en
P2093
Arlinghaus RB
Kardinal C
Schmidt EK
P304
P356
10.1182/BLOOD.V98.6.1773
P407
P577
2001-09-01T00:00:00Z